These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23327191)

  • 21. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
    Lee KH; Chang HJ; Han SW; Oh DY; Im SA; Bang YJ; Kim SY; Lee KW; Kim JH; Hong YS; Kim TW; Park YS; Kang WK; Shin SJ; Ahn JB; Kang GH; Jeong SY; Park KJ; Park JG; Kim TY
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):843-51. PubMed ID: 23314736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
    Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
    J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
    Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
    Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
    Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
    Duran G; Cruz R; Simoes AR; Barros F; Giráldez JM; Bernárdez B; Anido U; Candamio S; López-López R; Carracedo Á; Lamas MJ
    J Chemother; 2020 Oct; 32(6):310-322. PubMed ID: 32441565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.
    Wu H; Xu C; Chen G; Wang J
    J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
    Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
    Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
    Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.